Sort
82,697 grants matching “vaccine development”
Epitope-Based Design and Modified RNA Platform for Bivalent Marburgvirus Vaccine
$756,658Alexander Bukreyev · University Of Texas Med Br Galveston · R01 · FY2022 · AI
Immunologic Basis for Broad Protection against Enteric Fever Salmonella
$756,625Marcelo B. Sztein · University Of Maryland Baltimore · U19 · FY2014 · AI
Development of a novel TB vaccine safer and more effective than BCG based on a precisely controlled replication-limited Mycobacterium tuberculosis engineered for optimal in vivo growth and clearance
$756,592Marcus Aaron Horwitz · University Of California Los Angeles · R01 · FY2025 · AI
Chemoenzymatic synthesis of bacterial polysaccharides
$756,592Hai Yu · University Of California At Davis · U01 · FY2017 · GM
Development of a hamster model for hepatitis B virus infection
$756,589Zhongde Wang · Utah State University · R01 · FY2024 · AI
Large Scale Synthesis of the Next Generation Synthetic Saponin Adjuvant TiterQuil
$756,567Philip O. Livingston · Adjuvance Technologies, Inc. · R44 · FY2017 · AI
COVID-19 Pandemic Mitigation, Community Economic and Social Vulnerability, and Opioid Use Disorder
$756,521Elaine L Hill · University Of Rochester · U01 · FY2022 · DA
Identification and Characterization of Entry Factors Critical for Rift Valley Fever Virus Infection and Pathogenesis
$756,494Gaya K. Amarasinghe · Washington University · R01 · FY2021 · AI
New approach for immune modulation against T1D
$756,491Weston Daniel · Evoq Therapeutics, Inc. · R44 · FY2024 · DK
Elucidating Genetic Determinants of Resistance to Lassa Hemorrhagic Fever
$756,479Pardis Christine Sabeti · Broad Institute, Inc. · R01 · FY2017 · AI
Elucidating Genetic Determinants of Resistance to Lassa Hemorrhagic Fever
$756,479Pardis Christine Sabeti · Broad Institute, Inc. · R01 · FY2016 · AI
Elucidating Genetic Determinants of Resistance to Lassa Hemorrhagic Fever
$756,479Pardis Christine Sabeti · Broad Institute, Inc. · R01 · FY2018 · AI
Psychological symptoms in healthcare workers following the COVID-19 pandemic and relationship to long-term cardiovascular risk
$756,453Ari Shechter · Columbia University Health Sciences · R01 · FY2024 · HL
Role of Follicular T Helper Cells In Enhancing Humoral Immunity and Protection
$756,405Rafi Ahmed · Emory University · U19 · FY2014 · AI
Defining the impact of interpersonal gut microbiota variation on oral cholera vaccine responsiveness
$756,395Ansel Hsiao · University Of California Riverside · R01 · FY2025 · AI
Innate and early B cell responses to V. cholerae
$756,227Jason B Harris · Massachusetts General Hospital · R01 · FY2015 · AI
Understanding the mechanisms of antibody-mediated transcytosis of ZIKV within the placenta
$756,174Mehul Shamal Suthar · Emory University · R01 · FY2022 · AI
Western States Node of the National Drug Abuse Treatment Clinical Trials Network
$756,158James L. Sorensen · University Of California, San Francisco · UG1 · FY2015 · DA
Rocky Mountain Spotted Fever Vaccine Development
$756,089Roman R. Ganta · University Of Missouri-Columbia · R01 · FY2022 · AI
Development of Inhaled CPZEN-45 For Tuberculosis Therapy
$756,053Anthony James Hickey · Research Triangle Institute · R01 · FY2020 · AI
Novel tools for measuring typhoid vaccine impact
$756,045Jason Randolph Andrews · Stanford University · R01 · FY2024 · AI
Kinetic and structural basis for SARS-CoV-2 RNA-dependent RNA polymerase specificity and inhibition
$755,988Kenneth Allen Johnson · University Of Texas At Austin · R01 · FY2025 · AI
Preventing HIV Transmission by Recently-Infected Drug Users
$755,987Samuel R Friedman · National Development And Research Institutes, Inc. · DP1 · FY2015 · DA
Molecular Interactions Of Lymphoid Cell Receptors
$755,976David Margulies · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI
PATHOGENESIS OF MUCOSAL TRANSMISSION/ACUTE SIV INFECTION
$755,940University Of Minnesota Twin Cities · R01 · FY2000 · AI